- Home
- DVS vs TIL Comparison
DVS vs TIL Comparison
Compare DVS & TIL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DVS
- TIL
- Stock Information
- Founded
- DVS 2011
- TIL 2018
- Country
- DVS Canada
- TIL United States
- Employees
- DVS N/A
- TIL N/A
- Industry
- DVS
- TIL Biotechnology: Pharmaceutical Preparations
- Sector
- DVS
- TIL Health Care
- Exchange
- DVS Nasdaq
- TIL Nasdaq
- Market Cap
- DVS 210.3M
- TIL 230.1M
- IPO Year
- DVS N/A
- TIL 2021
- Fundamental
- Price
- DVS $3.65
- TIL $24.49
- Analyst Decision
- DVS
- TIL Buy
- Analyst Count
- DVS 0
- TIL 5
- Target Price
- DVS N/A
- TIL $119.00
- AVG Volume (30 Days)
- DVS 313.9K
- TIL 310.3K
- Earning Date
- DVS 08-23-2025
- TIL 08-12-2025
- Dividend Yield
- DVS N/A
- TIL N/A
- EPS Growth
- DVS N/A
- TIL N/A
- EPS
- DVS N/A
- TIL N/A
- Revenue
- DVS N/A
- TIL N/A
- Revenue This Year
- DVS N/A
- TIL N/A
- Revenue Next Year
- DVS N/A
- TIL N/A
- P/E Ratio
- DVS N/A
- TIL N/A
- Revenue Growth
- DVS N/A
- TIL N/A
- 52 Week Low
- DVS $2.48
- TIL $9.70
- 52 Week High
- DVS $4.00
- TIL $92.00
- Technical
- Relative Strength Index (RSI)
- DVS N/A
- TIL 47.69
- Support Level
- DVS N/A
- TIL $21.80
- Resistance Level
- DVS N/A
- TIL $26.91
- Average True Range (ATR)
- DVS 0.00
- TIL 3.52
- MACD
- DVS 0.00
- TIL -0.37
- Stochastic Oscillator
- DVS 0.00
- TIL 35.14
About DVS Dolly Varden Silver Corporation Common Shares
Dolly Varden Silver Corp is a mineral exploration company. The company's primary business is the acquisition, exploration, evaluation, and development of exploration and evaluation assets. It is focused on exploration advancing the Kitsault Valley Project, which includes the Dolly Varden property and the Homestake Ridge property located in the Golden Triangle of British Columbia, Canada.
About TIL Instil Bio Inc.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor, or CoStAR, platform. Its pipeline includes ITIL-306 which expresses a CoStAR molecule designed to recognize, a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC, and renal cancer.